Open access
6,103
Views
19
CrossRef citations to date
0
Altmetric
Oncology
Real-world treatment patterns and outcomes of abemaciclib for the treatment of HR+, HER2− metastatic breast cancer
Gebra Cuyun Cartera Eli Lilly and Company, Indianapolis, IN, USACorrespondence[email protected]
https://orcid.org/0000-0002-6549-0069
, https://orcid.org/0000-0002-6549-0069
Kristin M. Sheffielda Eli Lilly and Company, Indianapolis, IN, USA
, Anala Gossaib Flatiron Health, Inc., New York, NY, USA
, Yu-Jing Huanga Eli Lilly and Company, Indianapolis, IN, USA
, Yajun Emily Zhua Eli Lilly and Company, Indianapolis, IN, USA
, Lee Bowmana Eli Lilly and Company, Indianapolis, IN, USA
, Emily Nash Smytha Eli Lilly and Company, Indianapolis, IN, USA
, Raina Mathurb Flatiron Health, Inc., New York, NY, USA
, Aaron B. Cohenb Flatiron Health, Inc., New York, NY, USA;c School of Medicine, New York University, New York, NY, USA
, Erik Rasmussenb Flatiron Health, Inc., New York, NY, USA
, Shreya Balakrishnab Flatiron Health, Inc., New York, NY, USA
, Claudia Morato Guimaraesa Eli Lilly and Company, Indianapolis, IN, USA
, Sarah Rybowskia Eli Lilly and Company, Indianapolis, IN, USA
& Andrew D. Seidmand Memorial Sloan Kettering Cancer Center, New York, NY, USA
show all
Pages 1179-1187
|
Received 04 Jan 2021, Accepted 26 Apr 2021, Published online: 20 May 2021
Reprints and Permissions
Permission is granted subject to the terms of the License under which the work was published. Permission will be required if your reuse is not covered by the terms of the License.
To request a reprint or commercial or derivative permissions for this article, please click on the relevant link below.
For more information please visit our Permissions help page.
Related research
People also read lists articles that other readers of this article have read.
Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.
Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.